Evidence map›Paper›PMID 32050627›Full record

ArticleJournal of clinical medicine2020

Urinary Liver-Type Fatty-Acid-Binding Protein Predicts Long-Term Adverse Outcomes in Medical Cardiac Intensive Care Units.

Hiroyuki Naruse, Junnichi Ishii, Hiroshi Takahashi, Fumihiko Kitagawa, Hideto Nishimura, Hideki Kawai, Takashi Muramatsu, Masahide Harada, Akira Yamada, Wakaya Fujiwara and 6 more

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Hiroyuki NaruseDepartment of Joint Research Laboratory of Clinical Medicine, Fujita Health University School of Medicine, Toyoake 470-1192, Japan.
Junnichi IshiiDepartment of Joint Research Laboratory of Clinical Medicine, Fujita Health University School of Medicine, Toyoake 470-1192, Japan.
Hiroshi TakahashiDivision of Statistics, Fujita Health University School of Medicine, Toyoake 470-1192, Japan.
Fumihiko KitagawaDepartment of Joint Research Laboratory of Clinical Medicine, Fujita Health University School of Medicine, Toyoake 470-1192, Japan.
Hideto NishimuraDepartment of Cardiology, Fujita Health University School of Medicine, Toyoake 470-1192, Japan.
Hideki KawaiDepartment of Cardiology, Fujita Health University School of Medicine, Toyoake 470-1192, Japan.
Takashi MuramatsuDepartment of Cardiology, Fujita Health University School of Medicine, Toyoake 470-1192, Japan.
Masahide HaradaDepartment of Cardiology, Fujita Health University School of Medicine, Toyoake 470-1192, Japan.
Akira YamadaDepartment of Cardiology, Fujita Health University School of Medicine, Toyoake 470-1192, Japan.
Wakaya FujiwaraDepartment of Cardiology, Bantane Hospital, Nagoya 454-8509, Japan.
Mutsuharu HayashiDepartment of Cardiology, Bantane Hospital, Nagoya 454-8509, Japan.
Sadako MotoyamaDepartment of Cardiology, Fujita Health University School of Medicine, Toyoake 470-1192, Japan.
Masayoshi SaraiDepartment of Cardiology, Fujita Health University School of Medicine, Toyoake 470-1192, Japan.
Eiichi WatanabeDepartment of Cardiology, Fujita Health University School of Medicine, Toyoake 470-1192, Japan.
Hideo IzawaDepartment of Cardiology, Bantane Hospital, Nagoya 454-8509, Japan.
Yukio OzakiDepartment of Cardiology, Fujita Health University School of Medicine, Toyoake 470-1192, Japan.
Fujita Health University · JP

Funding

JSPS KAKENHI 17K08995
6 · The paper itself

Abstract

We prospectively investigated the prognostic value of urinary liver-type fatty-acid-binding protein (L-FABP) levels on hospital admission, both independently and in combination with serum creatinine-defined acute kidney injury (AKI), to predict long-term adverse outcomes in 1119 heterogeneous patients (mean age; 68 years) treated at medical (non-surgical) cardiac intensive care units (CICUs). Patients with stage 5 chronic kidney disease were excluded from the study. Of these patients, 47% had acute coronary syndrome and 38% had acute decompensated heart failure. The creatinine-defined AKI was diagnosed according to the "Kidney Disease: Improving Global Outcomes" criteria. The primary endpoint was a composite of all-cause death or progression to end-stage kidney disease, indicating the initiation of maintenance dialysis therapy or kidney transplantation. Creatinine-defined AKI occurred in 207 patients, with 44 patients having stage 2 or 3 disease. During a mean follow-up period of 41 months after enrollment, the primary endpoint occurred in 242 patients. Multivariate Cox regression analyses revealed L-FABP levels as independent predictors of the primary endpoint (

Indexed as

acute kidney injurycardiac intensive care unitsliver-type fatty-acid-binding proteinlong-term outcomes

Identifiers

PMID32050627
PMCPMC7073895
OpenAlexW3004476155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.